Chemiluminescence Immunoassay Market Size to Hit USD 17.24 Bn by 2035

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Chemiluminescence Immunoassay Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Chemiluminescence Immunoassay Market

5.1. Covid-19: Chemiluminescence Immunoassay Industry Impact
5.2. Chemiluminescence Immunoassay Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Chemiluminescence Immunoassay Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Chemiluminescence Immunoassay Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Chemiluminescence Immunoassay Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Upsurge in demand for treatment monitoring and precautionary diagnosis
6.1.1.2. Growth in technological advancements in disease diagnosis and COVID19 pandemic
6.1.2. Market Restraints
6.1.2.1. Restraint 1
6.1.3. Market Opportunities
6.1.3.1. Opportunity 1
6.1.3.2. Opportunity 2

Chapter 7. Global Chemiluminescence Immunoassay Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Chemiluminescence Immunoassay Market Revenue by Market Players
7.1.1.2. Chemiluminescence Immunoassay Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Product TypeSuppliers
7.1.3.2. List of End-users

Chapter 8. Global Chemiluminescence Immunoassay Market, By Product Type

8.1. Chemiluminescence Immunoassay Market, by Component
8.1.1. Consumables
8.1.1.1. Market Revenue and Forecast
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast
8.1.3. Software & Services
8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Chemiluminescence Immunoassay Market, By Application

9.1. Chemiluminescence Immunoassay Market, by Application
9.1.1. Cardiology
9.1.1.1. Market Revenue and Forecast
9.1.2. Therapeutic Drug Monitoring
9.1.2.1. Market Revenue and Forecast
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast
9.1.4. Endocrinology
9.1.4.1. Market Revenue and Forecast
9.1.5. Autoimmune Disease
9.1.5.1. Market Revenue and Forecast
9.1.6. Infectious Disease
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast

Chapter 10. Global Chemiluminescence Immunoassay Market, By End-user

10.1. Chemiluminescence Immunoassay Market, by End-user
10.1.1. Clinical Laboratories
10.1.1.1. Market Revenue and Forecast
10.1.2. Hospitals
10.1.2.1. Market Revenue and Forecast
10.1.3. Pharmaceutical & Biotechnology Companies
10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Chemiluminescence Immunoassay Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product Type
11.1.2. Market Revenue Forecast by Application
11.1.3. Market Revenue Forecast by End-user
11.1.4. U.S
11.1.4.1. Market Revenue Forecast
11.1.5. Canada
11.1.5.1. Market Revenue Forecast
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type
11.2.2. Market Revenue Forecast by Application
11.2.3. Market Revenue Forecast by End-user
11.2.4. UK
11.2.4.1. Market Revenue Forecast
11.2.5. Germany
11.2.5.1. Market Revenue Forecast
11.2.6. France
11.2.6.1. Market Revenue Forecast
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type
11.3.2. Market Revenue Forecast by Application
11.3.3. Market Revenue Forecast by End-user
11.3.4. China
11.3.4.1. Market Revenue Forecast
11.3.5. India
11.3.5.1. Market Revenue Forecast
11.3.6. Japan
11.3.6.1. Market Revenue Forecast
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type
11.4.2. Market Revenue Forecast by Application
11.4.3. Market Revenue Forecast by End-user
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type
11.5.2. Market Revenue Forecast by Application
11.5.3. Market Revenue Forecast by End-user
11.5.4. GCC
11.5.4.1. Market Revenue Forecast
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Siemens Healthineers
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Abbott Laboratories
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. DiaSorin S.p.A.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Ortho Clinical Diagnostics
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Immunodiagnostic Systems
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Beckman Coulter Inc.
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Inova Diagnostics, Inc.
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Maccura Biotechnology Co., Ltd
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global chemiluminescence immunoassay market size was valued at USD 8.37 billion in 2025 and expected to reach of around USD 17.24 billion by 2035.

The global chemiluminescence immunoassay market is predicted to register a compound annual growth rate (CAGR) of around 7.98% during period 2026 to 2035.

North America led the global market in 2025 with largest market share on account of snowballing occurrence of chronic diseases and better-qualityand upgraded healthcare infrastructure.

Hospitals segment reported highest share of the revenue generated in 2025. This growth is attributed to snowballing number of uses of automated CLIA analyzers in oncology, therapeutic drug monitoring and companion diagnostics .

Enhancements are predictable during years to come with the progress of novel analytical platforms like 2D resolution for chemiluminescence multiplex immunoassay andflow-injection chemiluminescent immunoassay and magnetic nanoparticles chemiluminescence immunoassay. This would probably outcome in supplementary increases in the clinical effectiveness of antibody tests. Influences like intensifying pervasiveness of infectious and chronic diseases, technological progressions in POC testing products, and mounting patient consciousness of POC testing are few of the chief influences fueling the need of immunoassay depending upon POC testing and swift testing around the world. The chemiluminescence immunoassay analyzers market is presently a thriving one, as there has been upsurge in requirement f

Chemiluminescent immunoassay (CLIA) is a variation of the biochemical technique employed in immunology named standard enzyme immunoassay. They can also be utilized as diagnosis tools in medicine and further finds application in several other plentiful industries. The foremost benefit of this technology comprises sensitivity and its aptitude to be unpretentious by signals in the background. Correspondingly, the analyzers working below this principle are easier in operation and design.